Financial Performance and Segment Growth
Neogen Chemicals reported a strong start to FY27, with consolidated revenue reaching ₹250.29 crore. This growth was primarily anchored by high volumes across organo-lithium, inorganic, and battery chemical portfolios. The inorganic chemicals segment emerged as a standout performer, with revenue surging 158% to ₹57 crore.
Organic chemicals also showed steady growth, generating ₹194 crore, an 18% increase year-on-year. EBITDA margins expanded by 260 basis points to 19.3%, despite facing headwinds such as elevated shipping freight costs and temporary overheads related to the reconstruction of the Dahej facility. Net profit for the quarter stood at ₹17.11 crore, marking a significant 66.76% increase over the same period last year.
Strategic Updates and Infrastructure Progress
- Reconstruction of the Dahej replacement facility is nearly complete, with commercial production slated for Q2 FY27
- Cumulative insurance recoveries reach ₹164 crore, with a net claim receivable of ₹186 crore pending final settlement
- Neogen Ionics delivered ₹19 crore in revenue for the quarter, exceeding 50% of the total revenue generated in the previous full year
- The electrolyte plant has completed mechanical assembly and initiated trial runs, with commissioning targeted for H1 FY27
- Lithium electrolyte salt production remains on schedule for commissioning in H2 FY27 to meet global demand
Management Outlook and Future Guidance
Management has expressed high confidence in the company's trajectory, raising the standalone revenue guidance for FY27 to ₹950-1,050 crore. This optimism is fueled by the transition of capital investments into revenue-generating assets and the scaling of Neogen Ionics. The company is positioning itself as a trusted non-FEOC partner for global cell producers, particularly in the US market, to meet tax credit requirements by 2027.
Looking further ahead, Neogen expects current CAPEX projects to support a revenue potential of ₹2,400-2,900 crore by FY29. The proposed ₹600 crore QIP is intended to reduce debt and provide financial flexibility to capture emerging opportunities in the battery material and organo-lithium spaces.
What to Watch
- Commencement of commercial supplies to four international electrolyte manufacturers post-final plant trial approvals
- Progress of the USD 20 million equity contribution from strategic partner Morita, expected during Q2 and Q3 FY27
- Utilization levels of the organo-lithium capacity, which hit peak levels in Q1 FY27
- Implementation of the Government of India's proposed PLI scheme for battery components and its impact on raw material localization
Execution Milestone
FY27 represents a strategic turning point for Neogen Chemicals as our capital investment transitions into revenue-generating assets.
